Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
Vaccine, Volume 25, No. 11, Year 2007
Notification
URL copied to clipboard!
Description
Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA). Methods: These studies compared intramuscular, subcutaneous, and intradermal MVA at dosage levels ranging from 5 × 106-2.5 × 108 pfu. In Study IAVI-010, DNA vaccine was given as a prime at months 0 and 1, followed by MVA as a boost at months 5 and 8. In Study IAVI-011, MVA alone was given at months 0 and 2. Regular safety monitoring was performed. Immunogenicity was measured by the interferon (IFN)-γ ELISPOT assay on peripheral blood mononuclear cells (PBMC). Results: No serious adverse events were attributed to either vaccine; most adverse events were mild or moderate, although MVA resulted in some severe local reactions. Five vaccine recipients had at least one positive IFN-γ ELISPOT response, but none were sustained. Conclusion: This HIV-1 vaccine candidate was in general safe and well-tolerated. Local reactions were common, but tolerable. Detectable immune responses were infrequent. © 2006 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Peters, Barry S.
United Kingdom, London
King's College London
Jaoko, Walter G.
Kenya, Nairobi
University of Nairobi
Vardas, Eftyhia
South Africa, Johannesburg
Chris Hani Baragwanath Hospital
Panayotakopoulos, George
United Kingdom, London
King's College London
Fast, Patricia E.
United States, New York
International Aids Vaccine Initiative
Schmidt, Claudia
United States, New York
International Aids Vaccine Initiative
Gilmour, Jill W.
United States, New York
International Aids Vaccine Initiative
Bogoshi, Mampedi
South Africa, Johannesburg
Chris Hani Baragwanath Hospital
Omosa-Manyonyi, Gloria S.
Kenya, Nairobi
University of Nairobi
Dally, Len G.
United States, Rockville
The Emmes Corporation
Klavinskis, Linda
United Kingdom, London
King's College London
Farah, Bashir
Kenya, Nairobi
University of Nairobi
Tarragona, Tony
United Kingdom, London
Chelsea and Westminster Hospital
Bart, Pierre Alexandre
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Robinson, A. K.L.
South Africa, Tygerberg
South African Medical Research Council
Pieterse, Colleen
South Africa, Tygerberg
South African Medical Research Council
Stevens, Wendy Susan
South Africa, Johannesburg
Contract Laboratory Services
Thomas, Richard
United Kingdom, Merthyr Tydfil
Simbec Research Ltd
Barin, Burc
United States, Rockville
The Emmes Corporation
McMichael, Andrew James
United Kingdom, Oxford
John Radcliffe Hospital
McIntyre, James Alasdair
South Africa, Johannesburg
Chris Hani Baragwanath Hospital
Pantaleo, Giuseppe P.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Hanke, T.
United Kingdom, Oxford
John Radcliffe Hospital
Bwayo, Job J.
Kenya, Nairobi
University of Nairobi
Statistics
Citations: 117
Authors: 24
Affiliations: 11
Identifiers
Doi:
10.1016/j.vaccine.2006.11.016
ISSN:
0264410X
Research Areas
Genetics And Genomics
Infectious Diseases